

REFERENCES

1. Conney AH, Pantuck EJ, Hsiao K-C, et al. Enhanced phenacetin metabolism in human subjects fed charcoal-broiled beef. *Clin Pharmacol Ther* 1976;20:633-42
2. Crichton M. *The Lost World*. New York, NY: Ballantine Books; 1996: 189-190
3. Guengerich FP. Cytochrome P450 enzymes. *American Scientist* 1993;81: 440-47
4. Nelson DR, Koymans L, Kamataki T, et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. *Pharmacogenetics* 1996;6:1-42
5. Musso DL, Mehta NB, Soroko FE, et al. Synthesis and evaluation of the antidepressant activity of the enantiomers of bupropion. *Chirality* 1993;5: 495-500
6. Stevens JC, Wighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. *J Pharmacol Exp Ther* 1993;266:964-971
7. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. *Pharmacol Ther* 1997;73:67-74
8. Chirality [editorial]. *Lancet* 1990;336:1100-1101
9. Poulsen L, Arendt-Nielsen L, Brgsen K, et al. The hypoalgesic effect of tramadol in relation to CYP2D6. *Clin Pharmacol Ther* 1996;60:634-44
10. Inaba T, Nebert DW, Burchell B, et al. Pharmacogenetics in clinical pharmacology and toxicology. *Can J Physiol Pharmacol* 1995;73:331-338
11. Jefferson IW, Greist JH. Brussels sprouts and psychopharmacology: understanding the cytochrome P450 enzyme system. In: Jefferson JW, Greist JH; eds. *Psychiatric Clinics of North America: Annual of Drug Therapy*. Philadelphia, Pa: Saunders; 1996;3:205-222
12. Edwards DJ, Bellevue FH, Woster PM. Identification of 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. *Drug Metab Dispos* 1996;24:1287-1290
13. Agrawal AK, Shapiro BH. Imprinted overinduction of hepatic CYP2B1 and 2B2 in adult rats neonatally exposed to phenobarbital. *J Pharmacol Exp Ther* 1996;279:991-999
14. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochrome P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. *J Pharmacol Exp Ther* 1996;276:658-166
15. Larsen-Su S, Williams DE. Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine. *Drug Metab Dispos* 1996;24:927-931
16. Gonzalez FJ, Gelboin HV. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. *Drug Metab Rev* 1994;26:165-183
17. Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, ed. *Cytochrome P450 Structure, Mechanism, and Biochemistry*, 2nd ed. New York, NY: Plenum; 1995:473-535
18. Park BK, Pirmohamed M, Kitteringham NR. The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. *Pharmacol Ther* 1995;68:385-24
19. Koyama E, Chiba K, Tani M, et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. *J Pharmacol Exp Ther* 1996;275:21-30
20. Mimura M, Baba T, Yamazaki H, et al. Characterization of cytochrome P-450 2B6 in human liver microsomes. *Drug Metab Dispos* 1993;21: 1048-1056
21. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals; studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994;270:414-23

22. Nakajima T, Elovaara E, Gonzalez FJ, et al. Characterization of the human cytochrome P450 isozymes responsible for styrene metabolism. In: Sorsa M, Peltonen K, Vainio H, et al., eds. *Butadiene and Styrene: Assessment of Health Hazards*. fARC Scientific Publications 1993;127:101-108
23. Chang TKH, Weber GF, Crespi CL, et al. Differential activation of cyclophosphamide and ifosfamide by cytochromes P-450 2B and 3A in human liver microsomes. *Cancer Res* 1993;53:5629-5637
24. Baker MT, Olson MJ, Wang Y, et al. Isoflurane-chlorodifluoroethene interaction in human liver microsomes: role of cytochrome P4502B6 in potentiation of halothane metabolism. *Drug Metab Dispos* 1995;23:60-64
25. Heyn I, White RB, Stevens JC. Catalytic role of cytochrome P450286 in the N-demethylation of S-mephenytoin. *Drug Metab Dispos* 1996;24: 948-954
26. Ono S, Hatanaka T, Miyazawa S, et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. *Xenobiotica* 1996;26:1 155-166
27. Flammang AM, Gelboin HV, Aoyama T, et al. Nicotine metabolism by cDNA-expressed human cytochrome P-450s. *Biochemical Archives* 1992; 8: 1-8
28. Nakajima M, Yamamoto T, Nunoya K, et al. Role of human cytochrome P4502A6 in *o*-oxidation of nicotine. *Drug Metab Dispos* 1996;24: 1212-1217
29. Ketter TA, Jenkins JB, Schrueder DH, et al. Carbamazepine but not valproate induces bupropion metabolism. *J Clin Psychopharmacol* 1995;15: 327-333
30. Reidy GF, Mehta I, Murray M. Inhibition of oxidative drug metabolism by orphenadrine: in vitro and in vivo evidence for isozyme-specific complexation of cytochrome P-450 and inhibition kinetics. *Mol Pharmacol* 1989; 35:736-743
31. Guo Z, Raeissi S, White RB, et al. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. *Drug Metab Dispos* 1997;25:390-393
32. Goldstein I, de Morais SMF. Biochemistry and molecular biology of the human CYP2C subfamily. *Pharmacogenetics* 1994;4:285-299
33. Daniel HI, Edeki TI. Genetic polymorphism of S-mephenytoin 4'-hydroxylation. *Psychopharmacol Bull* 1996;32:219-230
34. Flockhart DA. Drug interactions and the cytochrome P450 system. *Clin Pharmacokinet* 1991;29(suppl 1):45-52
35. Kroemer HK, Eichelbaum M. It's in the genes, stupid: molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism [minireview]. *Life Sci* 1995;56:2285-2298
36. Edeki TI, He H, Wood AJJ. Pharmacogenetic explanation for excessive (i)-blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. *JAMA* 1995;274:16(1-1613
37. Dahl ML, Bertilsson L, Johansson I, et al. Pharmacogenetics and isozyme specific drug interactions in psychopharmacology [abstract]. *Neuropsychopharmacology* 1994;10:4885
38. BrOsen K. Are pharmacokinetic drug interactions with the SSRIs an issue? *Int Clin Psychopharmacol* 1996;1 I(suppl 1):23-27
39. Riesenman C. Antidepressant drug interactions and the cytochrome P450 system: a critical appraisal. *Psychopharmacology* 1995;15:845-99S
40. Price LH, Chamey DS, Delgado PL, et al. Fenfluramine augmentation in tricyclic-refractory depression. *J Clin Psychopharmacol* 1990;10:312-317
41. Carrière V, Berthou F, Baird S, et al. Human cytochrome P450 2E1

- (CYP2E1): from genotype to phenotype. *Pharmacogenetics* 1996;6: 203-211
42. Valentine JL, Lee S-T, Seaton MJ, et al. Reduction of benzene metabolism and toxicity in mice that lack CYP2E1 expression. *Toxicol Appl Pharmacol* 1996;141:205-213
 43. Lieber CS. Medical disorders of alcoholism. *N Engl J Med* 1995;333: 1058-(065)
 44. Kharasch ED, Flankins D, Maulz D, et al. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. *Lancet* 1996;347:1367-1371
 45. Watkins PB. Noninvasive tests of CYP3A enzymes. *Pharmacogenetics* 1994;4:171-184
 46. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. *J Clin Psychopharmacol* 1995;15: 387-398
 47. Li AP, Kaminski DL, Rasmussen A. Substrates of human hepatic cytochrome P450 3A4. *Toxicology* 1995;104:1-8
 48. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P450 in drug metabolism. *Drug Metab Rev* 1995;27:397-417
 49. Deeks SG, Smith M, Holodniy M, et al. HIV-1 protease inhibitors: a review for clinicians. *JAMA* 1997;277:145-153
 50. Greenblatt DL, von Moltke LL, Harmatz JS, et al. Interaction of triazolam and ketoconazole. *Lancet* 1995;345:191
 51. Neuvonen PJ, Jalava K-M. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. *Clin Pharmacol Ther* 1996; 60:54-61
 52. Ducharme MP, Slaughter RL, Warbasse LH, et al. Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin. *Clin Pharmacol Ther* 1995;58:617-624
 53. Saklad S. Communication in: *Clinical psychopharmacology online*. *Curr Afflness* 1996;15:19
 54. Villikka K, Kivistö KT, Backman JT, et al. Triazolam is ineffective in patients taking rifampin. *Clin Pharmacol Ther* 1997;61:8-14
 55. Ketter TA, Callahan AM, Post RM. Nefazodone relief of alprazolam interdose dysphoria: a potential therapeutic benefit of 3A3/4 inhibition [letter]. *J Clin Psychiatry* 1996;57:307
 56. Keogh A, Spratt P, McCosker C, et al. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. *N Engl J Med* 1995;333: 628-633
 57. Pollock BG. Recent developments in drug metabolism of relevance to psychiatrists. *Harv Rev Psychiatry* 1994;2:204-212
 58. Baumann P Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitor. *Clin Pharmacokinet* 1996;31:444-69
 59. Baumann P, Rochat B. Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. *Int Clin Psychopharmacol* 1995; 10(suppl 1): 15-21
 60. Meyer UA, Amrein R, Balant LP, et al. Antidepressants and drug-metabolizing enzymes: expert group report. *Acta Psychiatr Scand* 1996;93:71-79
 61. Rosenbaum JF. Drug interactions and the cytochrome P450 system: clinical implications for selective serotonin reuptake inhibitors. *Clin Pharmacokinetic* 1995;29(suppl 1):1-61
 62. Nemeroff CB, DeVane L, Pollock BG. Newer antidepressants and the cytochrome P450 system. *Am J Psychiatry* 1996;153:311-320
 63. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, I. *J Clin Psychopharmacol* 1996;16:273-285

64. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors, II. *J Clin Psychopharmacol* 1996;16:345-355
65. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. *Clin Pharmacokinet* 1997;32(suppl 1):1-21
66. Preskorn SH. Effects of antidepressants on the cytochrome P450 systems. *Am J Psychiatry* 1996;153:1655-1656
67. Nemeroff CB, DeVane CL, Pollock BG. Reply to SH Preskorn: effects of antidepressants on the cytochrome P450 system [letter]. *Am J Psychiatry* 1996;153:1656-1657
68. Preskorn SH. Drug-drug interactions [letter with reply]. *J Clin Psychiatry* 1996;57:223-225
69. DeVane CL. Reply to Preskorn SH: Drug-drug interactions [letter]. *J Clin Psychiatry* 1996;57:225-227
70. Spigset O, Carlborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. *Clin Pharmacol Ther* 1995; 58:399-403
71. Aspeslet LJ, Baker GB, Coutts RT, et al. The effects of desipramine and iprindole on levels of enantiomers of fluoxetine in rat brain and urine. *Chirality* 1994;6:86-90
72. Sproule BA, Otton V, Cheung SW, et al. CYP2D6 inhibition in patients treated with sertraline. *J Clin Psychopharmacol* 1997;17:102-109
73. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. *J Pharmacol Exp Ther* 1997;280:927-933
74. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. *Eur J Clin Pharmacol* 1996;51:73-78
75. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. *J Clin Psychopharmacol* 1994;14:90-98
76. Lasher TA, Fleishaker JC, Steenwyk RC, et al. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. *Psychopharmacology* 1991;104:323-327
77. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. *J Clin Psychopharmacol* 1994;14:375-376
78. Carrillo JA, Dahl ML, Svensson J-O, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. *Clin Pharmacol Ther* 1996;60:183-190
79. Rasmussen BB, Muenpüsch J, Pelkonen O, et al. Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. *Br J Clin Pharmacol* 1995;39:151-159
80. Jeppesen U, Loft S, Poulsen H, et al. A fluvoxamine-caffeine interaction study. *Pharmacogenetics* 1996;6:213-222
81. Koponen H, Leinonen E, Lepola U. Fluvoxamine increases the clozapine serum levels significantly. *Eur Neuropsychopharmacol* 1996;6:69-71
82. von Moltke L, Greenblatt D, Duan SX, et al. Inhibition of terfenadine metabolism in vitro byazole antifungal agents and by selective serotonin reuptake inhibitors: relation to pharmacokinetic interactions in vivo. *J Clin Psychopharmacol* 1996;16:104-112
83. Alderman J, Allison J, Chung M, et al. Desipramine with paroxetine or sertraline. In: *New Research Program and Abstracts of the 147th Annual Meeting of the American Psychiatric Association*; May 26. 1994; Philadelphia, Pa. Abstract NR610:215

84. Hamelin BA, Turgeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquine. *Clin Pharmacol Ther* 196;60:512-521
85. Catterson ML, Preskorn SH. Pharmacokinetics of selective serotonin reuptake inhibitors: clinical relevance. *Pharmacol Toxicol* 1996;78:203-208
86. Ring BJ, Binkley SN, Roskos L, et al. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro. *J Pharmacol Exp Ther* 1995;275: 1131-1135
87. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. *J Clin Psychopharmacol* 1997;17:107-109
88. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. *Br J Clin Pharmacol* 1996;41:149-156
89. Ball S, Ahern D, Kao J, et al. Venlafaxine (VF): effects on CYP2D6 dependent imipramine (IMP) and desipramine (DMP) 2-hydroxylation: comparative studies with fluoxetine (FLU) and effects on CYP1A2, CYP3A4 and CYP2C9. *Clin Pharmacol Ther* 1996;59:170
90. Hodgman MJ, Marlin TG, Krenzelok EE Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy. *Hum Exp Toxicol* 1997;16:14-17
91. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. *Am J Health Syst Pharm* 99;52:2799-2812
92. Barbhuiya RH, Buch AB, Greene DS. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan. *Br J Clin Pharmacol* 1996;42: 573-581
93. Preskorn SH, Magnus RD, Horst D, et al. Pharmacokinetic and pharmacodynamic effects of coadministration of nefazodone and desipramine to normal volunteers. In: *New Research Program and Abstracts of the 149th Annual Meeting of the American Psychiatric Association*; May 7, 1996; New York, NY. Abstract NR 195:120
94. Greene DS, Salazar DE, Dockens RC, et al. Coadministration of nefazodone and benzodiazepines, IV. A pharmacokinetic interaction study with lorazepam. *J Clin Psychopharmacol* 1995;15:409-416
95. Pollock BG, Sweet RA, Kirslmer M, et al. Bupropion plasma levels and CYP2D6 phenotype. *Ther Drug Monit* 1996;18:581-585
96. Preskorn SH. Should bupropion dosage be adjusted based upon therapeutic drug monitoring? *Psychopharmacol Bull* 1991;27:637-643
97. Jilka MU, Preskorn SH. A possible bupropion and imipramine interaction. *J Clin Psychopharmacol* 1997;17:118-119
98. Verhoeven CHJ, Vos RME, Bogaards JJP. Characterization and inhibition of human cytochrome P-450 enzymes involved in the in vitro metabolism of mirtazapine [abstract]. *Eur Neuropsychopharmacol* 1996;6(suppl 4):63
99. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. *Clinical Drug Investigations J Clin Psychiatry* 1998;59 (suppl 4)1997;13:376
100. Sternback H. The serotonin syndrome. *Am J Psychiatry* 1991;148: 705-713
101. Lejoyeux M, Adés J, Rouillon F. Serotonin syndrome: incidence, symptoms and treatment. *CNS Drugs* 1994;2:132-143
102. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. *Neurology* 1995;45:219-223
103. Mills KC. Serotonin syndrome. *Am Fam Physician* 1995;52:1475-1482

104. Hoes M1, Zeijpveld 1H. Mirtazapine as treatment for serotonin syndrome [letter]. *Pharmacopsychiatry* 1996;29:81
105. Pedrinola F, Szejnsznajd C, Lima N, et al. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: a randomized clinical trial. *Obes Res* 1996;4:549-554
106. Steinmuller W. Communication in: *Clinical psychopharmacology online*. *CurrAffilfness* 1997;16:19-20
107. Physicians' Desk Reference. Montvale, NJ: Medical Economics; 1997